title: Haplotypic arrangement in CYP3A locus is associated with side effects of proliferative signal inhibitors in renal transplant recipients.
authors: Stepan
authors: S
authors: Bandur
authors: Jan
authors: J
authors: Petrasek
authors: Petra
authors: P
authors: Hribova
authors: Eva
authors: E
authors: Novotna
authors: Irena
authors: I
authors: Brabcova
authors: Ondrej
authors: O
authors: Viklicky
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D016022:Case-Control Studies; D049109:Cell Proliferation / Q000187:drug effects; D051544:Cytochrome P-450 CYP3A / Q000235:genetics*; D000068338:Everolimus; D006239:Haplotypes; D006801:Humans; D006949:Hyperlipidemias / Q000235:genetics / Q000276:immunology; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects*; D011507:Proteinuria / Q000235:genetics* / Q000276:immunology; D012189:Retrospective Studies; D015398:Signal Transduction; D020123:Sirolimus / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D007166:Immunosuppressive Agents; D000068338:Everolimus; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D020123:Sirolimus